Nucleic Acid-Based Drugs Against Emerging Zoonotic Viruses

References

• Smith KF , GoldbergM, RosenthalSet al. Global rise in human infectious diseases. J. R. Soc. Interface11 (101), 20140950 (2014).
   PubMed Web of Science ®Google Scholar
• WHO . Ebola situation report. http://apps.who/int/ebola/en/ebola-situation-reports.
   Google Scholar
• Tekmira . TKM-Ebola & TKM-Ebola-Guinea. www.tekmira.com/portfolio/tkm-ebola.php.
   Google Scholar
• Geisbert TW , RobbinsM, GeisbertJBet al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet375, 1896–905 (2010).
   PubMed Web of Science ®Google Scholar
• Thi EP , MireCE, LeeACHet al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature521, 362–365 (2015).
   PubMed Web of Science ®Google Scholar
• Wellcome Trust. New trial of TKM-Ebola treatment to start in Sierra Leona. www.wellcome.ac.uk/news/media-office/press-releases/2015/WTP058880.htm.
   Google Scholar
• Sanchez A , GeisbertTW, FeldmanHet al. Filoviradae: Marburg and Ebola viruses. In : Fields Virology. KnipeDM, HowleyPM ( Eds). Lippincott Wiliams and Wilkins, PA, USA, 1409–1448 (2006).
   Google Scholar
• Lazarus R , LimPL. Avian influenza: recent epidemiology, travel-related risk, and management. Curr. Infect. Dis. Rep.17 (456), 1–9 (2015).
   Google Scholar
• Johnson NP , MuellerJ. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull. Hist. Med.76, 105–115 (2002).
   PubMed Web of Science ®Google Scholar
• Fire A , XuS, MontgomeryMKet al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature391, 806–811 (1998).
   PubMed Web of Science ®Google Scholar
• Kanasty R , DorkinJR, VegasAet al. Delivery materials for siRNA therapeutics. Nat. Mater.12, 967–977 (2013).
   PubMed Web of Science ®Google Scholar
• Geisbert TW , HensleyLE, KaganEet al. Post exposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J. Infect. Dis.193, 1650–1657 (2006).
   PubMed Web of Science ®Google Scholar
• Arbutus Biopharma . http://investor.tekmira.com/releasedetail.cfm?releaseID=534328.
   Google Scholar
• Arbutus Biopharma . http://investor.tekmira.com/releasedetail.cfm?releaseID=865208.
   Google Scholar
• Ursic-Bedoya R , MireCE, RobbinsMet al. Protection against lethal Marburg virus infection mediated by lipid encapsulated small interfering RNA. J. Infect. Dis.209, 562–570 (2014).
   PubMed Web of Science ®Google Scholar
• Thi EP , MireCE, Ursic-BedoyaRet al. Marburg virus infection in nonhuman primates: therapeutic treatment by lipid-encapsulated siRNA. Sci. Transl. Med.6 (250), 1–9 (2014).
   Web of Science ®Google Scholar
• Schlingensiepen R , SchlingensiepenK-H. Antisense oligonucleotides – highly specific tools for basic research and pharmacology. In : Antisense – From Technology to Therapy. SchlingensiepenR, BryschW, SchlingensiepenK-H ( Eds). Blackwell Science, Victoria, Australia, 3–28 (1997).
   Google Scholar
• Zamecnik PC , StephensonML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA75, 280–284 (1978).
   PubMed Web of Science ®Google Scholar
• Stephenson ML , ZamecnikPC. Inhibition of Rous sarcoma viral translation by a specific oligodeoxyribonucleotde. Proc. Natl Acad. Sci. USA75, 285–288 (1978).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials Database. https://clinicaltrials.gov/ct2/results?term=antisense&search=search.
   Google Scholar
• Sanghvi YS . Antisense oligonucleotides: progress, opportunities and challenges. In : Nucleic Acid-Based Drugs. WongJP ( Ed.). Future Science Ltd, London, UK (2013).
   Google Scholar
• Sterling J . Antisense drugs finally turning the corner. Genetic Engineering and Biotechnology News33 (18), 10–12 (2013).
   Google Scholar
• Zhang T , ZhaoP, ZhangWet al. Antisense oligonucleotide inhibits avian influenza virus H5N1 replication by single chain antibody delivery system. Vaccine29, 1558–1564 (2011).
   PubMed Web of Science ®Google Scholar
• Jin Y , ZhangG, HuYet al. Inhibition of highly pathogenic avian H5N1 influenza virus propagation by RNA oligonucleotides targeting the PB2 gene in combination with celecoxib. J. Gene Med.13, 243–249 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang T , WangTC, ZhaoPSet al. Antisense oligonucleotides targeting the RNA binding region of the NP gene inhibit replication of highly pathogenic avian influenza virus H5N1. Int. Immunopharmacol.11 (12), 2057–2061 (2011).
   PubMed Web of Science ®Google Scholar
• Wu Y , ZhangG, LiYet al. Inhibition of highly pathogenic avian H5N1 influenza virus replication by RNA oligonucleotides targeting NS1 gene. Biochem. Biophys. Commun.365, 369–374 (2008).
   PubMed Web of Science ®Google Scholar
• Duan M , ZhouZ, LinRXet al. In vitro and in vivo protection against the highly pathogenic H5N1 influenza virus by an antisense phosphorothioate oligonucleotide. Antivir. Ther.13 (1), 109–114 (2008).
   PubMed Web of Science ®Google Scholar
• Iversen PL , WarrenTK, WellsJBet al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses4, 2806–2830 (2012).
   PubMed Web of Science ®Google Scholar
• Swenson DL , WarfieldKL, WarrenTKet al. Chemical modifications of antisense morphino oligomers enhance their efficacy against Ebola virus infection. Antimicrob. Agents Chemother.53 (5), 2089–2099 (2009).
   PubMed Web of Science ®Google Scholar
• Enterlein S , WarfieldKL, SwensonDLet al. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother.50 (3), 984–993 (2006).
   PubMed Web of Science ®Google Scholar
• Warfield KL , SwensonDL, OlingerGGet al. Gene-specific countermeasures against Ebola virus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog.2 (1), e1 (2006).
   PubMed Web of Science ®Google Scholar
• Warren TK , WhitehouseCA, WellsJet al. Advance antisense therapies for postexposure protection against lethal filovirus infections. Nature Med.16, 991–994 (2015).
   Google Scholar
• Warren TK , WhitehouseCA, WellsJet al. A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection. MBio6 (1), pii: e02344-14 (2015).
   Web of Science ®Google Scholar
• Head AE , IversenPL, SaoudJBet al. Safety and pharmacokinetic profiles of phosporodiamidate morphino oligomers with activity against Ebola virus and Marburg virus: results of two single-ascending-dose studies. Antimicrob. Agents Chemother.58 (11), 6639–6647 (2014).
   PubMed Web of Science ®Google Scholar
• Talon J , HorvathCM, PolleyRet al. Activation of interferon regulatory factor 3 is inhibited by the influenza virus NS1 protein. J. Virol.74, 7989–7996 (2000).
   PubMed Web of Science ®Google Scholar
• Ramanan P , ShabmanRS, BrownCSet al. Filoviral immune evasion mechanisms. Viruses3 (9), 1634–1649 (2011).
   PubMed Web of Science ®Google Scholar
• Sen GC , SarkarSN. Transcriptional signaling by double stranded RNA: role of TLR3. Cytokine Growth Factor Rev16, 1–24 (2005).
   PubMed Web of Science ®Google Scholar
• Nicodemus CF , BerekJS. TLR3 agonists as immunotherapeutic agents. Immunotherapy2 (2), 137–140 (2010).
   PubMed Web of Science ®Google Scholar
• Wong JP , ChristopherME, ViswanathanSet al. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine27, 3481–3483 (2009).
   PubMed Web of Science ®Google Scholar
• Wong JP , SaravolacEG, sabudaDet al. Prophylactic and therapeutic efficacies of poly(ICLC) against respiratory influenza virus infection in mice. Antimicrob. Agents Chemother.39, 2574–2576 (1995).
   PubMed Web of Science ®Google Scholar
• Barnard DL , DayCW, BaileyK, MontgomeryR, LairidsenLet al. Evaluation of immunomodulators, interferons, and known in vitro SARS-CoV inhibitors for inhibition of SARS-CoV replication in Balb/c mice. Antiv. Chem. Chemother.17, 275–284 (2006).
   PubMedGoogle Scholar
• Ichinohe T , KawaguchiA, TamuraSet al. Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect.9 (11), 1333–1340 (2007).
   PubMed Web of Science ®Google Scholar
• Wong JP , NagataLP, ChristopherMEet al. Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs. Vaccine23, 2266–2268 (2005).
   PubMed Web of Science ®Google Scholar
• Wong JP , ChristopherME, SalazarAMet al. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine25, 3175–3178 (2007).
   PubMed Web of Science ®Google Scholar
• Kende M . Prophylactic and therapeutic efficacy of poly (I,C)-LC against Rift Valley fever virus infection in mice. J. Biol. Response Mod.4, 503–511 (1985).
   PubMedGoogle Scholar
• Zhao J , Wohlford-LenaneC, ZhaoJet al. Intranasal treatment with Poly(I.C) protects aged mice from lethal respiratory virus infections. J. Virol.86 (21), 11416–11424 (2012).
   PubMed Web of Science ®Google Scholar